✦ LIBER ✦

Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: Results of a meta-analysis

✍ Scribed by Marina Berenguer; Ana Royuela; Javier Zamora

Book ID: 118285024
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 312 KB
Volume: 13
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.21035

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

242 HCC RECURRENCE AFTER LIVER TRANSPLAN

242 HCC RECURRENCE AFTER LIVER TRANSPLANTATION: ROLE OF IMMUNOSUPPRESSION WITH CALCINEURIN INHIBITORS

✍ M. Vivarelli; A. Cucchetti; G. La Barba; M. Cescon; M. Del Gaudio; G. Ercolani; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Immunosuppression and donor age with res

Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation

✍ Dimitrios N. Samonakis; Christos K. Triantos; Ulrich Thalheimer; Alberto Quaglia 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

In HCV cirrhotic patients after liver transplantation, survival and recurrence of HCV appears to be worsening in recent years. Donor age has been suggested as a cause. However, it is not clear if early and/or late mortality is affected and whether donor age is a key factor, as opposed to changes in

Ultrasound-Based Transient Elastography

Ultrasound-Based Transient Elastography for the Detection of Hepatic Fibrosis in Patients With Recurrent HCV After Liver Transplantation: Systematic Review and Meta-Analysis

✍ Adebajo, Corlan O. ;Talwalkar, Jayant A. ;Poterucha, John J. ;Kim, W. Ray ;Charl 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Improvement of renal function after the

Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction

✍ Javier F. Castroagudín; Esther Molina; Rafael Romero; Esteban Otero; Santiago To 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

Chronic renal dysfunction is a frequent and severe complication in solid-organ transplant recipients. Calcineurin inhibitors (CNIs) are the main pathogenic factors of renal dysfunction. Switching from CNIs to nonnephrotoxic drugs, such as mammalian target of rapamycin inhibitors (everolimus and siro